DarioHealth Corp

Healthcare US DRIO

0.7228USD
-0.0372(4.89%)

Last update at 2025-05-13T19:00:00Z

Day Range

0.710.78
LowHigh

52 Week Range

0.684.58
LowHigh

Fundamentals

  • Previous Close 0.76
  • Market Cap47.88M
  • Volume150547
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-51.07600M
  • Revenue TTM20.35M
  • Revenue Per Share TTM0.72
  • Gross Profit TTM 14.01M
  • Diluted EPS TTM-1.68

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -62.18900M -76.72900M -29.44500M -17.73600M -17.80300M
Minority interest - - - - -
Net income -62.19300M -76.76100M -28.98700M -17.76700M -17.80300M
Selling general administrative 16.49M 23.53M 12.76M 5.48M 5.47M
Selling and marketing expenses 30.32M 39.71M 15.23M 11.13M 10.31M
Gross profit 9.65M 3.96M 2.51M 2.60M 1.76M
Reconciled depreciation 4.72M 3.32M 0.19M 0.18M 0.21M
Ebit -56.81000M -76.49400M -29.90300M -17.70500M -17.59100M
Ebitda -52.39400M -72.98200M -30.15900M -17.50200M -17.38400M
Depreciation and amortization 4.42M 3.51M -0.25600M 0.20M 0.21M
Non operating income net other -5.37900M -0.23500M 0.46M -0.03100M -0.11500M
Operating income -56.81000M -76.49400M -29.90300M -17.70500M -17.68800M
Other operating expenses 84.47M 97.01M 37.48M 25.26M 25.08M
Interest expense 1.88M 0.43M 0.01M 0.00000M 0.00000M
Tax provision 0.00400M 0.03M - - -
Interest income 0.51M 0.04M 0.06M 0.02M 0.12M
Net interest income -2.17700M -0.04000M 0.01M -0.01100M -0.01800M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00400M 0.03M -0.45800M 0.03M -0.11500M
Total revenue 27.66M 20.51M 7.58M 7.56M 7.39M
Total operating expenses 66.47M 80.46M 32.42M 20.30M 19.45M
Cost of revenue 18.00M 16.55M 5.06M 4.96M 5.63M
Total other income expense net -5.37900M -0.23500M 0.46M -0.03100M -0.09700M
Discontinued operations - - - - -
Net income from continuing ops -62.19300M -76.76100M -29.44500M -17.73600M -17.80300M
Net income applicable to common shares -62.19300M -78.76600M -33.10300M -20.89100M -18.29600M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 96.39M 119.19M 100.77M 35.41M 24.57M
Intangible assets 5.40M 9.92M 12.46M - -
Earning assets - - - - -
Other current assets 1.54M 1.79M 1.78M 1.54M 0.42M
Total liab 38.24M 39.19M 15.22M 7.26M 5.67M
Total stockholder equity 58.14M 80.00M 85.55M 28.15M 18.89M
Deferred long term liab - 0.91M - - -
Other current liab 6.30M 6.59M 7.81M 3.02M 2.02M
Common stock 0.00300M 0.00300M 0.00200M - -
Capital stock 0.00300M 0.00300M 0.00200M 0.00000M 0.00000M
Retained earnings -349.36100M -285.85000M -222.01400M -143.24800M -110.14500M
Other liab - 0.91M 0.82M - -
Good will 41.64M 41.64M 41.64M - -
Other assets - 0.12M 0.08M 0.20M 0.22M
Cash 37.09M 49.36M 35.81M 28.59M 20.39M
Cash and equivalents - - - - -
Total current liabilities 12.49M 19.35M 14.38M 7.03M 5.22M
Current deferred revenue 1.00M 1.32M 1.20M 1.22M 1.22M
Net debt -7.54800M -21.30900M -35.52100M -28.05800M -19.62300M
Short term debt 4.07M 9.12M 0.27M 0.31M 0.32M
Short long term debt 3.95M 8.82M - - -
Short long term debt total 29.54M 28.05M 0.29M 0.53M 0.77M
Other stockholder equity 407.50M 365.85M 307.56M 171.40M 129.04M
Property plant equipment - 0.79M 0.70M 0.58M 1.41M
Total current assets 47.09M 65.52M 45.60M 34.13M 22.94M
Long term investments - - - - -
Net tangible assets - 28.44M 31.45M 28.37M 18.89M
Short term investments - - - - -
Net receivables 3.40M 7.14M 1.79M 1.70M 0.71M
Long term debt 24.59M 18.11M - - -
Inventory 5.06M 7.96M 6.23M 2.29M 1.41M
Accounts payable 1.13M 2.32M 5.11M 2.48M 1.66M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -0.61100M
Additional paid in capital - - - - -
Common stock total equity - 0.00300M 0.00200M - -
Preferred stock total equity - - - - -
Retained earnings total equity - -285.85000M -222.01400M -143.24800M -110.14500M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -5.02300M 0.12M 0.08M 0.20M 0.22M
Deferred long term asset charges - - - - -
Non current assets total 49.30M 53.67M 55.17M 1.28M 1.63M
Capital lease obligations 1.00M 1.12M 0.29M 0.53M 0.77M
Long term debt total - 18.11M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.57300M -0.40000M -1.50000M -0.11300M 0.08M
Change to liabilities -4.59800M -0.28800M 1.87M -0.54700M 2.44M
Total cashflows from investing activities -0.57300M -8.13400M -1.62200M -0.11300M 0.00600M
Net borrowings 23.79M 23.79M 23.79M 23.79M -
Total cash from financing activities 61.94M 65.77M 27.55M 25.25M 18.74M
Change to operating activities -1.90000M -1.41800M -0.07700M 0.54M 0.99M
Net income -62.19300M -76.76100M -29.44500M -17.73600M -17.80300M
Change in cash 13.52M 7.22M 8.19M 9.41M 7.28M
Begin period cash flow 35.95M 28.73M 20.54M 11.13M 3.72M
End period cash flow 49.47M 35.95M 28.73M 20.54M 11.00M
Total cash from operating activities -47.84500M -50.40900M -17.73600M -15.72500M -11.47000M
Issuance of capital stock 38.29M 64.88M 27.55M 25.25M 18.74M
Depreciation 4.72M 3.32M 0.19M 0.18M 0.21M
Other cashflows from investing activities -0.13100M -7.47300M -0.00400M -0.01500M -0.00100M
Dividends paid - - - - -
Change to inventory -1.72800M -2.23000M -0.87900M -0.03700M -0.19300M
Change to account receivables -5.10600M -0.35100M 0.55M -0.50400M 0.11M
Sale purchase of stock -0.13400M 65.77M 27.55M 25.25M -0.00100M
Other cashflows from financing activities 23.79M 0.89M -1.62200M -0.11300M 0.00100M
Change to netincome 16.98M 24.97M 11.10M 2.26M 3.76M
Capital expenditures 0.57M 0.26M 0.12M 0.10M 0.07M
Change receivables -5.10600M -0.35100M 0.55M -0.50400M 0.11M
Cash flows other operating 0.04M 0.93M -1.12400M 0.66M 0.01M
Exchange rate changes - - - - -
Cash and cash equivalents changes 13.52M 7.22M 8.19M 9.41M 7.28M
Change in working capital -10.89900M -2.57300M 0.42M -0.42900M 2.37M
Stock based compensation 16.98M 24.97M 11.10M 2.26M 3.76M
Other non cash items 3.56M 0.64M -8.95800M -9.99900M -0.00100M
Free cash flow -48.41800M -50.67000M -17.85400M -15.82300M -11.54100M

Peer Comparison

Sector: Healthcare Industry: Health Information Services

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DRIO
DarioHealth Corp
-0.0372 4.89% 0.72 - - 1.78 0.62 1.42 -0.5325
GEHC
GE HealthCare Technologies Inc.
-0.005 0.0067% 74.11 22.91 20.12 2.01 5.52 2.39 13.30
VEEV
Veeva Systems Inc Class A
-0.16 0.07% 241.28 54.61 33.22 12.83 6.73 11.14 58.84
MTHRF
M3 Inc
- -% 12.95 29.72 25.00 0.05 4.38 0.04 0.12
MTHRY
M3 Inc
-0.04 0.61% 6.54 31.84 26.25 0.05 4.60 0.04 0.12

Reports Covered

Stock Research & News

Profile

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

DarioHealth Corp

322 West 57th St., New York, NY, United States, 10011

Key Executives

Name Title Year Born
Mr. Erez Raphael CEO & Director 1973
Mr. Richard A. Anderson Pres 1969
Mr. Zvi Ben David CFO, Treasurer & Sec. 1961
Mr. Dror Bacher Chief Operating Officer 1975
Dov Oppenheim Co-Founder & Production Chief NA
Josh Fischer Sr. VP of Operations & Compliance NA
Claudia Levi Content & Communications Mang. NA
Mary Mooney VP of Marketing NA
Limor Drezner VP HR & Chief of Staff NA
Mr. Olivier R. Jarry Sr. VP of Strategy & Bus. Devel. 1961

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.